Evotec AG (NASDAQ:EVO – Get Free Report) was down 6.7% during trading on Tuesday. The company traded as low as $1.49 and last traded at $1.4550. 44,695 shares were traded during mid-day trading, a decline of 55% from the average session volume of 100,069 shares. The stock had previously closed at $1.56.
Analysts Set New Price Targets
Several research analysts recently issued reports on EVO shares. Weiss Ratings cut shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. HC Wainwright lifted their price objective on Evotec from $4.00 to $5.00 and gave the company a “buy” rating in a report on Friday, November 6th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $3.50.
View Our Latest Research Report on Evotec
Evotec Stock Down 1.4%
The stock has a fifty day moving average of $1.58 and a two-hundred day moving average of $2.40. The company has a current ratio of 2.32, a quick ratio of 2.19 and a debt-to-equity ratio of 0.65.
Institutional Inflows and Outflows
An institutional investor recently raised its stake in Evotec stock. Optiver Holding B.V. increased its stake in shares of Evotec AG (NASDAQ:EVO – Free Report) by 598.4% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 283,576 shares of the company’s stock after purchasing an additional 242,973 shares during the quarter. Optiver Holding B.V. owned about 0.08% of Evotec worth $709,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 5.81% of the company’s stock.
About Evotec
Evotec SE is a life sciences company headquartered in Hamburg, Germany, that provides drug discovery and development services to pharmaceutical, biotechnology and academic partners. Its work spans early-stage research through preclinical and clinical development, using expertise in areas such as biology, chemistry and data-driven drug discovery. The company supports programs across multiple therapeutic areas and develops both small-molecule and biologic medicines. Its Just-Evotec Biologics business focuses on the development and production of biologics, including services intended to help partners advance treatments from research toward clinical and commercial use.
Further Reading
- Five stocks we like better than Evotec
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
Receive News & Ratings for Evotec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec and related companies with MarketBeat.com's FREE daily email newsletter.
